/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
CORRECTING and REPLACING AmTrust Announces Quarterly Cash Dividends on Preferred Stock
NEW YORK–(BUSINESS WIRE)–The second paragraph of the release should read: The preferred dividends
will be payable June 17, 2019 to stockholders of record on June 1, 2019.
The corrected release reads:
AMTRUST ANNOUNCES QUARTERLY CASH DIVIDENDS ON PREFERRED STOCK
AmTrust Financial Services, Inc. (“AmTrust” or the “Company”) today
announced that its Board of Directors has approved a cash dividend per
share on the following series of non-cumulative preferred stock:
Series | Rate | Dividend | ||||
A | 6.750% | $0.421875 | ||||
B | 7.250% | $0.453125 | ||||
C | 7.625% | $0.476563 | ||||
D | 7.500% | $0.468750 | ||||
E | 7.750% | $0.484375 | ||||
F | 6.950% | $0.434375 | ||||
The preferred dividends will be payable June 17, 2019 to stockholders of
record on June 1, 2019.
About AmTrust Financial Services, Inc.
AmTrust Financial Services, Inc., a multinational insurance holding
company headquartered in New York, offers specialty property and
casualty insurance products, including workers’ compensation, commercial
automobile, general liability and extended service and warranty
coverage. For more information about AmTrust visit www.amtrustfinancial.com
Forward Looking Statements
This news release contains certain forward-looking statements that are
intended to be covered by the safe harbors created by the Private
Securities Litigation Reform Act of 1995. When we use words such as
“anticipate,” “intend,” “plan,” “believe,” “estimate,” “expect,” or
similar expressions, we do so to identify forward-looking statements.
Examples of forward-looking statements include the plans and objectives
of management for future operations, including those relating to future
growth of our business activities and availability of funds, and
estimates of the impact of material weaknesses in our internal control
over financial reporting, and are based on current expectations that
involve assumptions that are difficult or impossible to predict
accurately and many of which are beyond our control. Actual results may
differ materially from those expressed or implied in these statements as
a result of significant risks and uncertainties, including, but not
limited to, the ability to recognize the benefits of the merger,
non-receipt of expected payments from insureds or reinsurers, changes in
interest rates, a further downgrade in the financial strength ratings of
our insurance subsidiaries, changes in tax laws, the effect of the
performance of financial markets on our investment portfolio,
development of claims and the effect on loss reserves, accuracy in
projecting loss reserves, the cost and availability of reinsurance
coverage, the effects of emerging claim and coverage issues, changes in
the demand for our products, our degree of success in integrating
acquired businesses, the effect of general economic conditions, state
and federal legislation, regulations and regulatory investigations into
industry practices, our ability to timely and effectively remediate the
material weakness in our internal control over financial reporting and
implement effective internal control over financial reporting and
disclosure controls and procedures in the future, risks associated with
conducting business outside the United States, the impact of Brexit,
developments relating to existing agreements, breaches in data security
or other disruptions with our technology, any inability to keep pace
with technological advances, heightened competition, changes in pricing
environments, changes in asset valuations and the results of legal
proceedings, including litigation relating to the merger. The
projections and statements in this news release speak only as of the
date of this news release and we undertake no obligation to update or
revise any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be required
by law.
Contacts
AmTrust Financial Services
InvestorCom
Toll Free (877)
972-0090
Banks and Brokers call collect (203) 972-9300
[email protected]
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
Cannabis
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
Cannabis
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis2 weeks ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 weeks ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
Cannabis2 weeks ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis6 days ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis5 days ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Innocan5 days ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis1 day ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa